François Romagné - Concepedia

Author

François Romagné

Also Known As

F Romagne, F Romagné, F. ROMAGNE, F. ROMAGNÉ, F. Romagne, F. Romagné, FRANÇOIS ROMAGNÉ, Francois Romagne, Francois Romagné, François Romagne

130

Publications

Citations

H-Index

Concepts

All Affiliations

Inserm Innate Pharma (France)Centre d’Immunologie de Marseille-Luminy Centre National de la Recherche Scientifique Assistance Publique Hôpitaux de Marseille

About

François Romagné is an author at Inserm specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	3.5K
2	Allergy	5	5	1.3K
3	Natural Sciences	1	1	270
4	Biochemistry	1	1	270
5	Biomolecular Engineering	1	1	270

François Romagné

Publications

Citations

H-Index

Page 1

	Year	Citations
Human NK Cell Education by Inhibitory Receptors for MHC Class I Nicolas Anfossi, Pascale André, Sophie Guia, Immunity Autoimmune DiseaseAllergyMhc ClassImmunologyImmunologic Mechanism	2006	1.1K
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity Émilie Mamessier, Aude Sylvain, Marie‐Laure Thibult, Journal of Clinical Investigation Breast OncologyImmunologyImmune RegulationNk CellsImmunoediting	2011	666
Identification, activation, and selective<i>in vivo</i>ablation of mouse NK cells via NKp46 Thierry Walzer, Mathieu Bléry, Julie Chaix, Proceedings of the National Academy of Sciences	2007	450
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Ivan Perrot, Henri‐Alexandre Michaud, Marc Giraudon-Paoli, Cell Reports Cancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsImmunologyTumor Immunity	2019	404
Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors Charles A. Stewart, Fanny Laugier‐Anfossi, Frédéric Vely, Proceedings of the National Academy of Sciences	2005	391
Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells François Romagné, Pascale André, Pieter Spee, Blood	2009	388
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies Holbrook E. Kohrt, Ariane Thielens, Aurélien Marabelle, Blood	2013	274
Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates Patrick Dennler, Aristeidis Chiotellis, Eliane Fischer, Bioconjugate Chemistry ImmunologyGlycobiologyImmunotherapeuticsChemical BiologyMedicinal Chemistry	2014	270
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission Norbert Vey, Jean Bourhis, Nicolas Boissel, Blood	2012	268
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect Don M. Benson, Courtney E. Bakan, Shuhong Zhang, Blood	2011	199

Page 1